Inari Medical, Inc. (NARI)
| Market Cap | 3.15B |
| Revenue (ttm) | 358.92M |
| Net Income (ttm) | -22.36M |
| Shares Out | 53.65M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 665,491 |
| Open | 58.07 |
| Previous Close | 58.70 |
| Day's Range | 57.71 - 59.74 |
| 52-Week Range | 50.50 - 100.00 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 93.05 (+58.73%) |
| Earnings Date | Feb 21, 2023 |
About NARI
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore s... [Read more]
Financial Performance
In 2021, Inari Medical's revenue was $276.98 million, an increase of 98.31% compared to the previous year's $139.67 million. Earnings were $9.84 million, a decrease of -28.64%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for NARI stock is "Buy." The 12-month stock price forecast is $93.05, which is an increase of 58.73% from the latest price.
News
Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?
Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
Here's Why You Should Retain Inari Medical (NARI) Stock Now
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suf...
Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y
Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical Reports Third Quarter 2022 Financial Results
IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
IRVINE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suff...
Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline
Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical to Announce Third Quarter 2022 Financial Results
IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suf...
Inari Medical (NARI) Posts Positive Results of FLASH Registry
Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.
Inari Medical to Host First Analyst & Investor Day
IRVINE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ven...
Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock?
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venou...
Inari Medical to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...
Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical Announces Leadership Succession Plan
Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023 Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?
Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical to Announce Second Quarter 2022 Financial Results
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...
OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASES
ALISO VIEJO, Calif. , June 7, 2022 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular ...
Inari Medical Announces Launch of 2021 Ethos and Sustainability Report
IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venou...
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Inari Medical Inc's (NASDAQ: NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The increase over the prior year was driven by continued U.S. ...